Quantitative Cardiac Magnetic Resonance Imaging in Finding Heart Complications in Patients with Breast Cancer Receiving Chemotherapy
Inclusion Criteria
- Histologic diagnosis of breast carcinoma
- Scheduled to receive standard clinical therapy designed by their treating oncologist
- Patients should receive anthracycline as part of the recommended treatment
- Able to give informed consent
Exclusion Criteria
- Contraindication to contrast CMR including estimated glomerular filtration rate (eGFR) < 30 mls/min/1.73 m^2
- Uncontrolled serious concurrent illness
- Pregnancy or breast feeding
Massachusetts
Boston
PRIMARY OBJECTIVES:
I. To quantify the distributions and temporal changes of cardiac magnetic resonance (CMR) parameters during chemotherapy.
II. To identify CMR predictors of cardiotoxicity in patients receiving anthracycline +/- neoadjuvant therapy.
III. Demonstrate the incremental predictive value of CMR versus (vs.) transthoracic echocardiogram (TTE) and serum biomarkers in cardiotoxicity.
OUTLINE:
Patients undergo CMR at baseline, after completion anthracycline treatment, immediately after completion of all treatments (patients may receive targeted HER2+ positive treatment or other treatments between 3rd and 4th scans), and 12 months after completion of treatment.
After completion of study treatment, patients are followed up in 1 and 2 year intervals.
Trial Phase Phase NA
Trial Type Screening
Lead Organization
Dana-Farber Harvard Cancer Center
Principal Investigator
Reza Nezafat
- Primary ID 15-017
- Secondary IDs NCI-2016-00297
- Clinicaltrials.gov ID NCT02666378